Michael Platten, MD

@michael-platten.bsky.social

Neurologist, Chair of Neurology Brain Tumor Immunotherapy @dkfz.bsky.social @platten-lab.bsky.social @uniheidelberg.bsky.social Medical Faculty Mannheim Founder Tcelltech President @eanoassociation.bsky.social Ambassador for the @erc.europa.eu

Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/

Bild

The SynthImmune project by Heidelberg University& partner institutes advances a "bottom-up" synthetic biology approach to immunotherapies. Hoping they do well in the German government's Excellence Strategy—anticipating the announcement on 22 May. Perspective article: www.nature.com/articles/s41...

Bottom-up synthetic immunology - Nature Nanotechnology

This Perspective highlights bottom-up molecular engineering and modular nanobiotechnological approaches for developing effective immunotherapeutics and their potential in personalized medicine.

nature.com

🚀 New publication! We developed a PTPRZ1-specific TCR-T cell therapy for glioblastoma. 🔬 Key findings: ✅ Identified a PTPRZ1-reactive TCR from a vaccinated patient ✅ Kills glioblastoma cells with no off-target effects ✅ Eliminates tumors in murine brain models 🔗 www.nature.com/articles/s41...

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications

Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...

nature.com